HTA. Efficacies of HTA regimen for acute myeloid leukemia AML. J of Wannan Medical College HHT THP AML 1 DA AML

Transcription

1 HTA HHT THP Ara-C HTA AML ~ AML HTA 1 CR + CRi PR OR CR + PR DA 23 HTA 15 1 CR 11 PR 2 OR 13 DA 23 1 CR 14 PR 3 OR 17 HTA CR DA P > HTA AML R A DOI / j. issn Efficacies of HTA regimen for acute myeloid leukemia WEI Zhongling SU Guiping Department of Hematology The first Affiliated Hospital of Wannan Medical College Wuhu China Abstract Objective To evaluate the efficacy and adverse events of induction chemotherapy by combined regimen of homoharringtonine pirarubicin and cytarabine HTA for initially diagnosed acute myeloid leukemia AML. Methods The efficacies and adverse responses were retrospectively examined in 15 cases of AML treated with HTA regimen in our department between August 2006 and December The rates of complete remission CR partial remission PR and overall remission OR in one course of chemotherapy induction were summed up and compared with another group of patients controls n = 23 received dose-adjusted DA regimen. Results CR PR and OR were identified in 11 cases in 2 cases and in 13 cases in HTA group compared to 14 cases 3 cases and 17 cases respectively in DA group. Although HTA group had slightly higher CR than DA group yet the difference was not significant P > Conclusion HTA may be served as one of the regimens in induction chemotherapy for AML for the adverse reactions can be tolerated. Key words leukemia cytarabine homoharringtonine pirarubicin acute myeloid leukemia AML 1 DNR Ara-C ~ HTA 15 CR 50% ~ 60% 2 DNR CR 3-4 DNR AML 5 1 AML FAB M3 2 HHT THP Ara-C HTA AML15 DA 23 3 AML ~ DA liuwu66@ sohu. com yjssuguiping@ sohu. com.

2 HTA NR ORRCR + PR HHT 2 ~ 3 mg /d 5 ~ 7 d THP 10 ~ 20 mg / d 2 ~ 3 d Ara-C 100 ~ 150 mg / m 2 d 5 ~ 7 d DA DNR 40 ~ 60 mg / m 2 d 1 ~ 3 d Ara-C 100 ~ 150 mg / m 2 d 5 ~ 7 d SPSS % ± t Fisher P /L < h < 60 g /L 2 < /L 2. 1 HTA ~ ± 14. 7FAB h 10 9 /L 36 ~ 126 g /L 5 ~ /L 27 ~ 93 % DA ~ ± FAB M1 4 M2 16 M4 1 1 M ~ ~ ~ 109 g /L 8 ~ ~ 97 % 0 WHO 0 ~ Ⅳ < /L M1 3 M ~ FAB 5 CR CR CRi PR P > M1 M2 M4 M5 g /L HTA ± ± ± ± ± DA ± ± ± ± ± t P HTA 15 1 P > Fisher CR 11 PR 2 NR 2 OR CR 2 /2 8 /11 1 /2 DA 23 1 CR 14 PR 3 NR 6 OR CR 13 /20 1 /3 P = % CR PR NR OR HTA DA

3 P < /L WHO 3 Ⅲ ~ Ⅳ HTA DA HTA DA 3 d /L d HTA ± ± ± ± ± ± DA ± ± ± ± ± ± t P HTA 1 Ⅰ DA HTA Fisher P > U 4 HTA DA P HTA 15 4 ~ CR 18 95% CI ~ DA ~ % CI ~ DA 1 OS % HTA 1 OS 80. 0% P = DA 50% ~ 60% DNR DNR DNA α β DNA G2 6 7 TA DA THP 900 ~ 1100 mg /m 2 DNR 550 mg /m CR AML AML HHT

4 567 G1 G2 S HHT DNR DNA THP 12 THP HHT Ara-C HA DA 30% 18 HTA HA DA DA HHT DNR 13 HAD HTA 1 OS AML CR 65. 7% AML HTA HAA CR 65. 7% CR 78% 16 HAA HAD DA HTA HAA HAD DA CR 73% 67% 61% HAA HAD DA HTA AML CR 11 /15 DA 14 / HTA DA HTA DA HTA DA 13 /15 vs 23 /23 HTA DA /L /L Fazlina N Maha A Jamal R HHT 2. 5 mg / m 2 d1 17 et al. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia a sin Plesa C Chelghoum Y Plesa A gle-institution experience J. Cancer 2008 DA 78. 6% 14 CR HTA HTA AML J Berman E Heller G Santorsa J et al Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia J. Blood Lee JH Joo YD Kim H et al. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia J. Blood Fernandez HF Sun z Yao X et al. Anthracycline dose intensification in acute myeloid leukemia J. N EnglJ Med M Isuruo T Iidah Tsukagoshi S et al. 4'-O-tetrahydropyranyladriameycin as a potential new antitumor agent J. Cancer Res J. et al. Expression of multidrug resistance MDR proteins and in vitro drug resistance in acute leukemias J. Hematology

5 BACTEC MGIT BACTEC MGIT % 4 / % 1 / % 17 /30 BACTEC MGIT 960 P < BACTEC MGIT960 R A DOI / j. issn Diagnosis of tuberculous meningitis in children by modified Ziehl-Neelsen stain CAO Xiaona SHAO Yanxin GAO Qing SU Yi WEI Yuan FENG Jianchun Department of Pediatrics The First People's Hospital of Xinji City Xinji China Abstract Objective To assess the clinical value of applying modified Ziehl-Neelsen stain to diagnosis of tuberculous meningitis in children. Methods The cerebrospinal fluid CSF was detected in 30 cases confirmed clinically as tuberculous meningitis by BACTEC MGIT 960 culture system centrifuged smear test and modified Ziehl-Neelsen stain respectively and the results were compared for the positive accuracy. Results The positive rate by BACTEC MGIT 960 culture system centrifuged smear test and modified Ziehl-Neelsen stain was 13. 3% 4 / % 1 /30 and 56. 7% 17 /30 respective- ly and the difference was significant P < Conclusion The modified Ziehl-Neelsen stain can be more sensitive in rapid diagnosis of tuberculous meningitis in children and is worthy of wider clinical recommendation. Key words cerebrospinal fluid modified Ziehl-Neelsen stain BACTEC MGIT 960 culture system Mycobacterium tuberculosis jj_jyj@ 163. com @ qq. com. 10 Harvey P Roger B D Jeffrey K et al. Comparison of three remisson in duction regimens and two postinduction strategies for the treat- 15. HAA ment of acute nonlymphocytic leukemia a cancer and leukemia 236 J group B study J. Blood Jin JI Wang JX Chen FF et al. Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia a multicentre open-label randomised controlled phase 3 trial J. 91 J HA DA J Lancet Oncol O'Brien S Kantarjian H Keadng M et al. Homoharringtoalne ther- 13. HA apy induces responses in patients chronic myelogenous Leukemia in J. late chronic phase J. Blood DEA DHA J Zhong LY Li QH Huang ZL et al. Regimen containing perarubicin for the treatment of newly diagnosed young patients with acute myeloid leukemia J. Ai Zheng